GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

Welcome back, Rotoballers! Tonight, we have a seven-game main slate, headlined by a nightcap of Celtics at Nuggets. These ...

Richard Leadbetter of Digital Foundry shared an interesting opinion when it comes to his expectations for the Switch 2. In a ...

Take a look at our DFS (daily fantasy sports) guide and recommendations. We've pooled our experts years of experience to give ...